3,5-Dinitrocatechol

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
3,5-Dinitrocatechol
Accession Number
DB02105  (EXPT01233)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
OR 486 / OR-486
Categories
UNII
VK0VA22GY2
CAS number
Not Available
Weight
Average: 200.1058
Monoisotopic: 200.00693587
Chemical Formula
C6H4N2O6
InChI Key
VDCDWNDTNSWDFJ-UHFFFAOYSA-N
InChI
InChI=1S/C6H4N2O6/c9-5-2-3(7(11)12)1-4(6(5)10)8(13)14/h1-2,9-10H
IUPAC Name
3,5-dinitrobenzene-1,2-diol
SMILES
OC1=CC(=CC(=C1O)[N+]([O-])=O)[N+]([O-])=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UCatechol O-methyltransferaseNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-HydroxyestradiolThe metabolism of 2-Hydroxyestradiol can be decreased when combined with 3,5-Dinitrocatechol.
AmisulprideThe therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Amisulpride.
AripiprazoleThe therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Aripiprazole.
AsenapineThe therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Asenapine.
AzaperoneThe therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Azaperone.
BifeprunoxThe therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Bifeprunox.
BlonanserinThe therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Blonanserin.
BrexpiprazoleThe therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Brexpiprazole.
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with 3,5-Dinitrocatechol.
CariprazineThe therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Cariprazine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
3870203
PubChem Substance
46507481
ChemSpider
3094995
BindingDB
50017846
ChEMBL
CHEMBL168276
HET
DNC
PDB Entries
1vid / 3a7e / 3bwm / 3bwy / 5fhq / 5fhr / 5lsa / 6i3c / 6i3d

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.605 mg/mLALOGPS
logP1.71ALOGPS
logP1.25ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)4.38ChemAxon
pKa (Strongest Basic)-6.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area132.1 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity44.67 m3·mol-1ChemAxon
Polarizability15.39 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6447
Blood Brain Barrier-0.8405
Caco-2 permeable-0.5546
P-glycoprotein substrateNon-substrate0.7887
P-glycoprotein inhibitor INon-inhibitor0.804
P-glycoprotein inhibitor IINon-inhibitor0.9727
Renal organic cation transporterNon-inhibitor0.9491
CYP450 2C9 substrateNon-substrate0.769
CYP450 2D6 substrateNon-substrate0.8708
CYP450 3A4 substrateNon-substrate0.5762
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9154
CYP450 3A4 inhibitorNon-inhibitor0.8585
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.5959
CarcinogenicityNon-carcinogens0.6665
BiodegradationNot ready biodegradable0.8925
Rat acute toxicity2.7748 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8597
hERG inhibition (predictor II)Non-inhibitor0.9107
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dinitrophenols. These are organic aromatic compounds containing a benzene that carries a single phenol group and exactly two nitro groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenols
Sub Class
Nitrophenols
Direct Parent
Dinitrophenols
Alternative Parents
Nitrobenzenes / Nitroaromatic compounds / Catechols / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Propargyl-type 1,3-dipolar organic compounds / Organic oxoazanium compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds
show 2 more
Substituents
Dinitrophenol / Nitrobenzene / Nitroaromatic compound / Catechol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Monocyclic benzene moiety / C-nitro compound / Organic nitro compound / Organic oxoazanium
show 11 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
O-methyltransferase activity
Specific Function
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOP...
Gene Name
COMT
Uniprot ID
P21964
Uniprot Name
Catechol O-methyltransferase
Molecular Weight
30036.77 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on December 02, 2019 06:05